JP2023517753A5 - - Google Patents

Info

Publication number
JP2023517753A5
JP2023517753A5 JP2022555952A JP2022555952A JP2023517753A5 JP 2023517753 A5 JP2023517753 A5 JP 2023517753A5 JP 2022555952 A JP2022555952 A JP 2022555952A JP 2022555952 A JP2022555952 A JP 2022555952A JP 2023517753 A5 JP2023517753 A5 JP 2023517753A5
Authority
JP
Japan
Prior art keywords
seq
region
binding
heavy chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022555952A
Other languages
English (en)
Japanese (ja)
Other versions
JP7749575B2 (ja
JP2023517753A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/056879 external-priority patent/WO2021185934A1/en
Publication of JP2023517753A publication Critical patent/JP2023517753A/ja
Publication of JP2023517753A5 publication Critical patent/JP2023517753A5/ja
Application granted granted Critical
Publication of JP7749575B2 publication Critical patent/JP7749575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022555952A 2020-03-18 2021-03-17 B7h4に結合する抗体 Active JP7749575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164059.6 2020-03-18
EP20164059 2020-03-18
PCT/EP2021/056879 WO2021185934A1 (en) 2020-03-18 2021-03-17 Antibodies binding to b7h4

Publications (3)

Publication Number Publication Date
JP2023517753A JP2023517753A (ja) 2023-04-26
JP2023517753A5 true JP2023517753A5 (cg-RX-API-DMAC7.html) 2024-03-27
JP7749575B2 JP7749575B2 (ja) 2025-10-06

Family

ID=69846241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555952A Active JP7749575B2 (ja) 2020-03-18 2021-03-17 B7h4に結合する抗体

Country Status (21)

Country Link
US (4) US20210292418A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121456A1 (cg-RX-API-DMAC7.html)
JP (1) JP7749575B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220154757A (cg-RX-API-DMAC7.html)
CN (1) CN115298221A (cg-RX-API-DMAC7.html)
AR (1) AR121599A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021236906A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015572A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168613A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002494A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014603A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220521A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000181A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080714A (cg-RX-API-DMAC7.html)
IL (1) IL296362A (cg-RX-API-DMAC7.html)
MX (1) MX2022009936A (cg-RX-API-DMAC7.html)
MY (1) MY210125A (cg-RX-API-DMAC7.html)
PE (1) PE20230444A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551960A1 (cg-RX-API-DMAC7.html)
TW (1) TW202200624A (cg-RX-API-DMAC7.html)
WO (1) WO2021185934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
KR20220154757A (ko) 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
KR20240004949A (ko) * 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2023046047A1 (zh) * 2021-09-27 2023-03-30 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
GB202202171D0 (en) * 2022-02-17 2022-04-06 Bivictrix Ltd Novel methods of therapy
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN107660214B (zh) * 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
WO2018021301A1 (ja) 2016-07-26 2018-02-01 静岡県 抗b7-h4抗体
LT3592769T (lt) * 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
AU2018363922B2 (en) * 2017-11-08 2025-06-12 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
CN108148137B (zh) * 2017-12-29 2021-03-23 中国人民解放军第四军医大学 一种b7h4/1e10单克隆抗体及其应用
KR20220154757A (ko) 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체

Similar Documents

Publication Publication Date Title
TWI845767B (zh) 抗人Claudin18.2抗體及其應用
US20190300624A1 (en) Her3 antigen-binding molecules
CN113015749A (zh) 靶向cd3的抗体、双特异性抗体及其用途
AU2019412754B2 (en) BTN3A binding proteins and uses thereof
US20200308308A1 (en) Vista antigen-binding molecules
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
JP2021517457A5 (cg-RX-API-DMAC7.html)
WO2022121980A1 (zh) 抗SIRPα抗体及其用途
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
US12304951B2 (en) Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
WO2022060832A1 (en) Cd33 antibodies
CN114591434A (zh) 抗Siglec15抗体及其制备方法和用途
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
TWI789399B (zh) 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TWI889920B (zh) 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途
JP7844430B2 (ja) 抗gprc5d抗体に対する抗イディオタイプ抗体
RU2808138C1 (ru) Антитело, нацеливающееся на cd3, биспецифическое антитело и их применение
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도
JP2024520552A (ja) 抗cd79b抗体に対する抗イディオタイプ抗体
KR20260013450A (ko) 이중 특이적 항원 결합 분자 및 이의 응용
CN119285769A (zh) 多特异性抗体及其医药用途
HK40048219A (en) Cd3-targeting antibody, bispecific antibody and use thereof
HK40048219B (en) Cd3-targeting antibody, bispecific antibody and use thereof